Founder & Chief Executive Officer

Drug Hunter on LinkedIn: MYT1, Pan-RAF, Pan-RAS and More: Dec. '23 Compound Collection |…

Drug Hunter on LinkedIn: 2023 Novel Large Molecule FDA Drug Approvals

Vertex Pharmaceuticals's NaV1.8 inhibitor for Ph. III pain | Drug Hunter posted on the topic

Drug Hunter on LinkedIn: Targeting Post-Transcriptional RNA-Modification with a First-to-Clinic…

Research Analyst, Modalities & Drug Design Concepts

Drug Hunter™ is an essential knowledge platform for industry R&D innovators turning molecules into medicines. The Research Analyst-Modalities and Drug Design will play a crucial role in expanding the current Drug Hunter content by creating reviews on exciting modalities and emerging concepts in drug design.

Sign up with Google

Sign in with Google